BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

BioLineRx Price Performance

Shares of BLRX stock opened at $0.43 on Thursday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The company has a market capitalization of $34.06 million, a PE ratio of -0.95 and a beta of 1.48. The firm’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.63. BioLineRx has a 12 month low of $0.39 and a 12 month high of $1.93.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. Analysts predict that BioLineRx will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On BioLineRx

A number of institutional investors have recently made changes to their positions in the stock. PVG Asset Management Corp acquired a new position in BioLineRx in the 2nd quarter valued at about $70,000. Atria Investments Inc grew its holdings in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC acquired a new position in shares of BioLineRx in the second quarter valued at approximately $462,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.